Kedrion Biopharma Inc. announced today that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the Immunoglobulin therapy Yimmugo® in the US, following its Biologic License Application (BLA) approval by the US Food and Drug Administration (FDA). Immunoglobulin therapies, such as Yimmugo®, are essential in managing Primary Immunodeficiencies (PID), which affect approximately 500,000 people in the US. They play a crucial role in preventing infections, enhancing immune function, and improving the quality of life for patients.
“Kedrion is proud of our role in addressing rare immune system deficiencies by making Yimmugo® accessible to patients in the US,” said Ugo Di Francesco, CEO of Kedrion Biopharma. “Biotest has been an excellent collaborator, and we look forward to exploring further opportunities. This significant new arrangement is part of our larger strategy to address unmet patient needs in antibody immunodeficiency.”
Kedrion expects to begin distributing this medicine in the US early next year. This is the latest example of Kedrion’s commitment to expand patient access to plasma-derived therapies.
